Research Article

hsa_circ_0077837 Alleviated the Malignancy of Non-Small Cell Lung Cancer by Regulating the miR-1178-3p/APITD1 Axis

Shanlin Xu,1 Yanyan Jiang,2 and Yaqian Duan3

1Department of Oncology, Zibo Central Hospital, Zibo, Shandong 255000, China
2Department of Respiration, Zibo Central Hospital, Zibo, Shandong 255000, China
3Department of Respiratory and Critical Care Medicine, Shandong Province Chest Hospital, Jinan, Shandong 250000, China

Correspondence should be addressed to Yaqian Duan; duanyaqian150@163.com

Received 8 September 2021; Revised 3 December 2021; Accepted 1 February 2022; Published 9 March 2022

Objective. circRNAs were a group of the most promising molecular biomarkers for clinical prognosis and diagnosis of non-small cell lung cancer (NSCLC). It was a pity that academic circle still struggled to figure out how circRNAs acted on NSCLC. This article aimed to study the function and mechanism of hsa_circ_0077837 in NSCLC progression.

Methods. Cell viability was measured via CCK-8, while apoptosis was evaluated with flow cytometry. Transwell assay and scratch test were used to detect invasion and migration, respectively. Dual-luciferase reporter gene assay verified the regulatory effect of miR-1178-3p on hsa_circ_0077837 and miR-1178-3p on apoptosis-inducing, TAF9-like domain 1 (APITD1). TUNEL assay and immunohistochemistry were used to assess cells apoptosis and proliferation in lung tumor tissues in mice.

Results. Hsa_circ_0077837 and APITD1 expression were suppressed in NSCLC tissues and cells, and miR-1178-3p level was promoted. High amount of hsa_circ_0077837 intensely prevented cell proliferation, migration, and invasion, promoted cell apoptosis in vitro, and delayed tumor growth in mice. Further analysis indicated that hsa_circ_0077837 acted as a miR-1178-3p sponge to stabilize APITD1, the target of miR-1178-3p. Mechanistically, we discovered that hsa_circ_0077837 could prevent proliferation, viability, migration, and invasion of NSCLC cells through stimulating the miR-1178-3p/APITD1 pathway.

Conclusion. Collectively, our findings validated that hsa_circ_0077837 served as a miR-1178-3p sponge by targeting APITD1 that alleviated NSCLC progression.

1. Introduction

Lung cancer is the most dreadful malignancy worldwide and the most common pathogenesis of cancer death. Every year, more than 1.83 million patients were diagnosed with lung cancer. According to histopathological classification, it has two classic types: one is non-small cell lung cancer (NSCLC) and the other is small cell lung cancer (SCLC) [1]. Among them, NSCLC takes up top 1 for nearly 80–85% proportion. NSCLC is able to be divided into three subtypes, namely adenocarcinoma type, squamous cell carcinoma type, and large cell carcinoma type [2]. So far, despite the progress in treatment, the overall prognosis of NSCLC is still unsatisfactory, and we feel awful to realize its 5-year survival rate was only 15% [3, 4]. In recent years, the high incidence of NSCLC has posed a serious threat to human health. Thus, our objective, discovering the potential pathogenesis related to NSCLC, is meaningful and clinical-oriented to find out novel therapeutic targets.

Circular RNAs (circRNAs) belong to noncoding RNA molecules in a closed stable structure formed by reverse splicing [5, 6]. It has been revealed by researchers that circRNAs are new hopeful molecular biomarkers for diagnosis and prognosis for serious diseases as well as potential of targeted therapy targets [7, 8] with high stability, high conservation among species, and tissue specificity. It has been demonstrated that circRNA participates in various kinds of processes in cancers, such as proliferation, apoptosis, and metastasis. Increasing numbers of circRNAs was also found involved in NSCLC by regulating different
processes [9, 10]. For instance, circPTK2 inhibited epithelial-mesenchymal transition and metastasis induced by TGF-beta by means of controlling TIF1gamma in NSCLC [11]. circRNA CDR1as/HOXA9/miR-641 axis decrease the risk of cisplatin resistance in NSCLC through regulating stemness [12]. Moreover, several circRNAs were also reported to serve as potential biomarkers for NSCLC, such as circFARSA, circRNA-102231, and circRNA-1008876 [13]. Upexpression of circRNA-102231 was observed in NSCLC with significant clinical meaning [14]. These results suggested that circRNA might provide new ideas to develop new targeted therapies and drugs for NSCLC.

The previous study suggested that hsa_circ_0077837 is significantly downregulated in the tumor tissues in NSCLC and has diagnostic potential for this cancer [15], indicating that hsa_circ_0077837 serves to be a tumor suppressor for NSCLC. However, the regulatory method of hsa_circ_0077837 underlying NSCLC development remained vague. Hence, the research aimed to discover the role of hsa_circ_0077837 in the development of NSCLC.

2. Materials and Methods

2.1. Patients and Specimens. Patients with NSCLC (n = 110) were enrolled in this study. NSCLC tissues and paracancerous normal tissues adjacent to tumor tissues were resected from each subject. The tissues were transferred into liquid nitrogen immediately. Written informed consent from all patients before clinical trial, and the clinical trial was all in line with ethical requirements of the Declaration of Helsinki.

2.2. Cell Culture and Transfection. BEAS-2B (bronchial epithelial line) and H1650, H1975, NCI-H1359, HCC827, and A549 cells (NSCLC lines) were purchased from American Type Culture Collection (ATCC). All cells were cultured in flasks with Dulbecco’s Modified Eagle’s Medium (DMEM) adding 10% fetal bovine serum (FBS) at 37°C and 96% air-4% CO2. Overexpressing and silencing of hsa_circ_0077837 or APITD1, miR-1178-3p mimics or inhibitor and their corresponding controls were synthesized by GenePharma (Shanghai, China). For transfection, these vectors were transfected into H1650 cells when the confluence of H1650 cells reached 70–90% by Lipofectamine vectors were transfected into H1650 cells when the confluence of H1650 cells reached 70–90% by Lipofectamine

2.3. Total RNAs Extraction and Analysis by RT-PCR. Total RNAs from tissues and cells mentioned above were purified by MiniBEST RNA Extraction Kit (TaKaRa, Japan) in an RNase-free environment and manner. The quality of the total RNAs was detected by NanoDrop. miRNA-complementary cDNA was obtained from total RNAs by means of a PrimeScript™ RT kit (TaKaRa, Japan) according to stem-loop RT primers (RiboBio, Guangzhou, China). Then, Bio-Rad IQ5 real-time PCR was coused with SYBR Green PCR Master Mix (Bio-Rad, USA) to analyze cDNA. The PCR program was 95°C warm-up for 32 s, followed by 42 cycles of (95°C for 5 seconds, plus 61°C for 10 s). The relative gene expression was analyzed by 2−ΔΔCt methods that normalized to the internal control GAPDH or U6. The primer sequences were shown as follows: hsa_circ_0077837 forward, 5'-CCTGGAGAACATGCCAAGGG-3', and reverse, 5'-TCCA TCTGACACAGGCTTACT-3'; GAPDH forward, 5'-CGGAGTCAACGGATTTGTGC-3', and reverse, 5'-TCTCC GTTCTCAGCCTTGAC-3'; miR-1178-3p forward, TGCT CACTGTCTCC, and reverse, 5'-GAAACTGTCTG CGTATCTC-3'; U6 forward, 5'-CTCGCTTCGGCCAGGCA C-3', and reverse, 5'-AACCCTAATTCCTACT CTAC-3'.

2.4. Western Blot Assay. Protein from tissues or cells was released by using RIPA lysis buffer. We measured the protein concentration by BCA protein assay kit (Bio-Rad, USA). 20 mg protein was obtained by using SDS-PAGE gels. Then, the extracted protein was moved by electricity to a PVDF membrane (Millipore, Bedford, MA, USA), then, interacted with specific primary antibody anti-APITD1 (1:1000; #PA5-24846, RIRD : AB_2542346; Invitrogen, Shanghai, China) or anti-GAPDH (1:1000; #MA1-16757, RIRD : AB_568547; Invitrogen, Shanghai, China) overnight after being treated with 5% fat-free milk solution for 60 min at room temperature. Followed by washed with TBST, the membranes were incubated with secondary antibody conjugated with Alexa Fluor® Plus 488 goat-anti-mouse IgG (1:1000; #A32723, RIRD : AB_2633275; Invitrogen, Shanghai, China) at room temperature for 1 h. GeneGnome 5 (Synoptics Ltd., UK) was used to observe the protein bands on the membranes after coloration via ECL chemiluminescience kit (Advansa, USA).

2.5. Cell Counting Kit-8 (CCK-8) Assay. The cell viability was tested via a CCK-8 kit under manufacturing instruction. Briefly, transfected cells were collected by centrifugation and dispersed at 1 × 10^5 cells/mL. Then, 100 μL cell supernatant was transferred into each well of three 96-well plates and incubated for separately 12 h, 24 h, 48 h, and 72 h at 37°C and 95% air-5% CO2, respectively. 10 μL CCK-8 solution was then mixed at each well and incubation for 2 h. The optical density (OD) value was read by using a microplate reader (Bio-Rad, CA, USA) at 450 nm. Cell viability was determined by measuring the absorbance (optical density) at the wavelength of 450 nm (OD_{450}) of cell supernatants.

2.6. Apoptosis Analysis. NSCLC cell apoptosis was analyzed after dying with annexin V/FITC and read on flow cytometry (BD Biosciences, Franklin Lakes, NJ, USA). Cells were collected and cleaned through PBS solution twice. Cell suspension was mixed with annexin V/FITC to dye at room temperature in darkness. Flow cytometry was then used to measure the apoptosis rate as the standard operation procedure of the equipment. The voltage of FSC, SSC, and
fluorescent channel for computer detection were adjusted. The excitation and emission wavelength were 488 nm and 530 nm, separately.

2.7. Wound Healing Test. 1 × 10^5 cells/mL cells were prepared with DMEM (10% FBS) after 48 h of transfection and transferred into transparent 6-well plates at 1 mL/well. Afterward, the plates stayed in 37°C and 95% air and 5% CO₂ for 24 h. A sterile pipette was used to draw a line across the bottom of each well, and the width of the initial diameter was measured. 1 mL fresh DMEM medium with 10% FBS was served as culture into each well, and the plates stayed in 37°C and 95% air-5% CO₂ for 24 h. After incubation again, the width of the wound was measured in the same previous way. The relative wound width was equal to (second wound width of the wound was measured in the same previous way).

2.8. Transwell Experiment. Transwell chambers were inoculated after being precoated via Matrigel (BD Biosciences, USA). Transfected cells (1×10^6 cells/mL) were transferred into the upper tier of the transwell chamber. 500 µL serum-free cell suspensions were transferred to the upper tier of the transwell chamber. 500 µL DMEM with 10% FBS served as culture in the lower tier of the transwell chamber and then stayed in 37°C and 95% air-5% CO₂ for 24 h to facilitate cells to invade. After invasion, cells received treatment with 4% formaldehyde and staining with 0.1% crystal violet. The electron microscope (Nikon, Tokyo, Japan) counted the number of invasive cells by using the ImageJ software.

2.9. Luciferase Assay. DNA fragments containing the wild-type (WT) or mutant (Mut) hsa_circ_0077837 and APITD1 3’UTR were subcloned into the pmiR-GLO vector (pGL3-Basic). Then, 50 ng pmiR-GLO vector containing the WT or Mut-hsa_circ_0077837 fragment and the 3’UTR region of APITD1 were cotransfected into human HEK293T cells with miR-1178-3p mimics or miR-1178-3p NC by Lipofectamine 2000 reagent (Invitrogen, USA) and grown in 24-well plates. The reporter assay was performed with the dual-luciferase reporter assay was performed with the dual-luciferase (Promega) at 48 h after transfection. Normalization processing was performed to analyze the relative activity of firefly luciferase based on Renilla luciferase.

2.10. Xenograft Model In Vivo. The BALB/c nude mice (4–6 weeks old, male, n = 20) came from the Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China), randomly classified into 4 groups, including 2 × 10^6 H1650 cells stably expressing hsa_circ_0077837 or siRNA of hsa_circ_0077837 in 100 µL PBS solution, and were separately injected into the nude mouse vein. The mice injected with H1650 cells act as the model group. The mice without any treatment act as the control group. Tumor size and weight were examined every seven days and the tumor volume was measured as volume = 0.5 × D (longest diameter) × d² (diameter perpendicular to the longest diameter). The pathological changes in the tumor was detected by immunochemistry. Our assays were under the approval of the Animal Experimental Ethics Committee of Shandong Province Chest Hospital in advance. All experimental procedures with the use of animals are carried out at Shandong Province Chest Hospital in strictly accordance with the Guidelines for the Management of Laboratory Animals and other ethical requirements.

2.11. Immunohistochemistry. Xenograft tissues in mice were fixed into paraffin and then sliced into 4 μm paraffin sections. To dewax thorough, sections were dipped in xylene solution and gradient ethanol solution from 80% to 100%. Then, tissues were washed with 0.01 M citrate buffer to antigen retrieval. Subsequently, the sections stayed at 3% at near 30°C for 14 min. The sections stayed with goat serum for 28 min at room temperature after getting rid of H₂O₂. Primary antibodies anti-Ki-67 (#sc-23900, RRID: AB_627859, Santa Cruz, USA) was bonded to the sections at 4°C overnight. Sections were bonded with horseradish peroxidase (HPR)-labeled secondary antibody (#BA1051, Boster, China) in the proportion of 1:200 for 28 min at room temperature sequentially. After washing with PBS for 2 times, sections were sealed in neutral resin so as to be observe under the microscope.

2.12. TUNEL Assay. Tumor tissue sections removed protein through proteinase K for 28 min at room temperature followed by incubation with 0.1% TritonX-100 and 3% H₂O₂ for at least 10 min. After that, the TUNEL assay was performed in terms of the TUNE kit (Roche, USA) instructions. In brief, sections were biotinylated and stained by 10 µL TUNEL solution. Afterward, dehydration was performed by gradient ethanol after washing with clean water for at least 3 times. Sections was dewaxed by using xylene and confined in neutral resin. All sections were enlarged and recorded under the microscope.

2.13. Statistical Analysis. SPSS 21.0 served as our statistical analysis tool, and the data were present as mean ± standard error of mean (SEM) with three independent experiments. The comparison for two groups received Student’s t-test, while more than three groups were analyzed by ANOVA followed by Tukey’s post hoc test. P < 0.05 means that there was statistically significant difference.

3. Results

3.1. Hsa_circ_0077837 Expression Was Lower in NSCLC Tissues and Cell Lines. It has been demonstrated that hsa_circ_0077837 expression was lower in the tumor tissues in comparison with that in nontumor tissues. In order to further confirm the results, hsa_circ_0077837 expression was examined in NSCLC cell lines and tissues by qRT-PCR. This study indicated that hsa_circ_0077837 level was downregulated in the tumor tissues (n = 110) in comparison with adjacent tissues (n = 110) (t = 87.64, P < 0.001; Figure 1(a)). Furthermore, hsa_circ_0077837 expression was declined in NSCLC cell lines in comparison with control cell line BEAS-2B, and it showed the most significant downregulation in H1650 cells (F(5, 12) = 21.62, P = 0.000013, Figure 1(b)). Therefore, H1650 cells were used for further study.
3.2. Hsa_circ_0077837 Inhibited Cell Viability, Migration, and Invasion While Enhanced Apoptosis of NSCLC Cells. To confirm hsa_circ_0077837 function on NSCLC cells, hsa_circ_0077837 loss- and gain-of-function assays were performed in H1650 cells. As shown in Figure 2(a), hsa_circ_0077837 level was elevated or declined in H1650 cells by transfection with over-hsa_circ_0077837 or si-hsa_circ_0077837, respectively (F(2, 6) = 1857, P < 0.001). CCK-8 analysis indicated that H1650 cell absorbance at 450 nm was dramatically decreased by over-hsa_circ_0077837 while increased by si-hsa_circ_0077837 in comparison with the control, indicating that hsa_circ_0077837 exerts a positive effect on H1650 cell viability (Figure 2(b)). The transwell assay indicated that number of invaded H1650 cells was inhibited in over-hsa_circ_0077837 group and increased by si-hsa_circ_0077837 in comparison with the control, which suggested that hsa_circ_0077837 suppressed NSCLC cell invasion (Figure 2(c), F(2, 6) = 292.7, P < 0.001). Wound width was higher in the over-hsa_circ_0077837 group and lower in si-hsa_circ_0077837 group, revealing that hsa_circ_0077837 suppressed NSCLC cell migration (Figure 2(d), F(2, 6) = 171.4, P < 0.001). Flow cytometry indicated that the apoptosis rate was elevated when over-expressing hsa_circ_0077837 while decreased when suppressing expression of hsa_circ_0077837 (Figure 2(e), F(2, 6) = 388.8, P < 0.001). These results demonstrated that overexpression of hsa_circ_0077837 inhibited H1650 cell viability, migration, and invasion and enhanced apoptosis.

3.3. Hsa_circ_0077837 Served as a Sponge of miR-1178-3p. cirRNAs were revealed as miRNA sponges via binding with miRNAs and weakening their actions. Aimed to explore the mechanism underlying hsa_circ_0077837, we analyzed hsa_circ_0077837 bioinformatic targets via CircInteractome (https://circinteractome.nia.nih.gov/). The results showed that miR-1178-3p was identified as probable target of hsa_circ_0077837 (Figure 3(a)). Further analysis demonstrated that miR-1178-3p expression level was dramatically increased in NSCLC tissues (n = 110) (Figure 3(b), t = 227.7, P < 0.001). Luciferase reporter assays depicted that miR-1178 mimics repressed WT-hsa_circ_0077837 luciferase activity (n = 3, t = 5.263, P = 0.0062) while not affected in Mut-hsa_circ_0077837 group (n = 3, t = 0.2685, P = 0.8083) (Figure 3(c)). We could conclude that hsa_circ_0077837 served as miR-1178-3p sponge.

3.4. APITD1 Was a Downstream Molecule of miR-1178-3p. To know downstream molecule of miR-1178-3p, TargetScan predicted the targets of miR-1178-3p. Results showed that APITD1 had the binding sites for miR-miR-1178-3p (Figure 4(a)). Dual-luciferase reporter assays revealed that miR-1178-3p upregulation had significant effect on luciferase activity of WT-APITD1 (n = 3, t = 8.547, P = 0.001) rather than Mut-APITD1 (n = 3, t = 1.049, P = 0.3532) (Figure 4(b)). Further analysis depicted that APITD1 expression was downregulated in NSCLC tissues (n = 110) in comparison with adjacent tissues (n = 110) (Figure 4(c), t = 77.57, P < 0.001). In addition, we found that miR-1178-3p mimics could decrease APITD1 expression level while miR-1178-3p inhibitor exerted an adverse effect, suggesting that APITD1 expression level was negatively correlated with miR-1178-3p expression level (F(2, 6) = 1108, P < 0.001, Figure 4(d)). These results demonstrated that APITD1 was a direct target of miR-1178-3p.

3.5. Hsa_circ_0077837 Hindered Cell Growth of NSCLC by Regulating the miR-1178-3p/APITD1 Axis. To clarify whether hsa_circ_0077837 exerted effects by regulating the miR-1178-3p/APITD1 pathway, rescue assays were performed. Results demonstrated that miR-1178-3p mimics and downregulation of APITD1 could facilitate cell proliferative, migratory (miR-
1178-3p: *F (2, 6) = 165.7, P < 0.001; APITD1: *F (2, 6) = 280.1, 
P < 0.001), and invasive (miR-1178-3p: *F (2, 6) = 240.4, 
P < 0.001; APITD1: *F (2, 6) = 171.2, P < 0.001) capabilities 
while repress apoptosis compared with the control group 
(Figures 5(a)–5(d)). However, the opposite results were 
obtained under miR-1178-3p depletion and APITD1 elevation. 
Rescue assays demonstrated that miR-1178-3p elevation or 
APITD1 depletion rescued the function of hsa_circ_0077837 
overexpression on NSCLC cell viability, migration (F (3, 8) = 
86.7, P < 0.001), invasion (F (3, 8) = 104.6, P < 0.001), and 
apoptosis (F (3, 8) = 60.55, P < 0.001) (Figures 5(e)–5(h)). 
These data demonstrated that hsa_circ_0077837 exerted an 
antitumor function via the miR-1178-3p/APITD1 pathway.

3.6. Hsa_circ_0077837 Elevation Inhibited NSCLC Tumor-
genesis In Vivo. In order to know the in vivo effect of 
hsa_circ_0077837 on NSCLC tumor progression, nude mice 
model with xenograft tumors were established. Figure 6(a) 
displayed hsa_circ_0077837 level was successfully elevated 
or suppressed by injecting H1650 cells stably expressing 
hsa_circ_0077837 or si-hsa_circ_0077837 into mice (F (2, 12) = 
2311, P < 0.001). The tumor volume and weight (F (2, 12) = 
160, P < 0.001) were reduced under hsa_circ_0077837 
overexpression while elevated under hsa_circ_0077837 
depletion (Figure 6(b)). Ki-67 immunohistochemistry illus-
trated that positive Ki-67 cells in xenograft tumors was 
declined in over-hsa_circ_0077837 group while increased
under hsa_circ_0077837 downregulation (F (2, 12) = 98.14, P < 0.001, Figure 6(c)), suggesting that overexpression of hsa_circ_0077837 inhibited tumor growth. In addition, qRT-PCR analysis presented that miR-1178-3p expression was depleted under hsa_circ_0077837 upregulation while elevated under hsa_circ_0077837 deficiency (F (2, 12) = 3626, P < 0.001, Figure 6(d)). However, the expression of APITD1 showed the opposite results, as detected by western blot (F (2, 12) = 158.9, P < 0.001) (Figure 6(e)). Hsa_circ_0077837 increased TUNEL-positive cells in xenograft tumors, while si-hsa_circ_0077837 decreased TUNEL-positive cells, implying that circ_0077837 increased tumor cell apoptosis ((F (2, 12) = 135.1, P < 0.001, Figure 6(f)). These results depicted that hsa_circ_0077837 hindered NSCLC development by regulating the miR-1178-3p/APITD1 axis.

4. Discussion

Lung cancer is the leading position of malignant tumors which causes the most cases of death worldwide [16]. Despite the progress in treatment, it is still a highly invasive and fatal disease. Lung cancer is generally not diagnosed until advanced [17]. As a result, it is a top concern to clarify its internal molecular mechanism and finally develop ideal prognostic markers and therapy methods. Herein, we succeeded to prove that hsa_circ_0077837 was significantly downregulated in NSCLC tissues and cell lines. Function and mechanism analysis of hsa_circ_0077837 indicated that hsa_circ_0077837 alleviated the progression of NSCLC by regulating the hsa-miR-1178/EDNRA axis.

circRNAs are another type of endogenous noncoding RNAs, which are commonly present in humans because of their rich content, conserved sequence, stable structure, and other characteristics [18]. circRNA has the characteristics of extensiveness, diversity, stability, and conservation, and it can modulate physiological functions such as transcription regulation and protein translation [19]. Benefited by high-throughput sequencing techniques, various important circRNAs have been proved to have relation with NSCLC, such as hsa_circ_0001073 and hsa_circ_0001495 [20–22]. In the previous study, ROC curve analysis strongly proved the function of hsa_circ_0077837 and hsa_circ_0001821 to act as useful biomarkers for LUAD and LUSC. Of them, hsa_circ_0077837 showed significantly downregulated in the tumor tissues both in LUAD and LUSC [15]. Consistently, in the present study, we validated that hsa_circ_0077837 level was significantly downregulated in NSCLC tissues and cell lines, implying that hsa_circ_0077837 could exert tumor suppressor role in NSCLC. Increasing evidence has proved that circRNAs exerted crucial effects on the regulation of various kinds of tumor development as well as in NBSCCL. For instance, circSATB2 was abnormally high-expressed in NSCLC cells and tissues which may promote NSCLC cell growth [23]. circRNA_102179 promoted the proliferative, migratory, and invasive abilities in NSCLC through the miR-330-5p/HMGB3 axis [24]. Additionally, several circRNAs

Figure 3: Hsa_circ_0077837 served as a miR-1178-3p sponge. (a) The potential binding site between hsa_circ_0077837 and miR-1178-3p was predicted by using CircInteractome. (b) Relative expression of miR-1178-3p was detected by qRT-PCR in 110 NSCLC tissues. U6 acts as a control. The data were presented as mean ± SEM, *** P < 0.001, adjacent vs. tumor group. (c) Luciferase reporter assays detected the regulatory effect of miR-1178-3p to hsa_circ_0077837. The data were presented as mean ± SEM, ** P < 0.01, miR-1178-3p mimics group vs. miR-1178-3p NC group.
also present potential clinical diagnosis value in NSCLC, including circ_0005280, circFARSA, and circRNA_102231 [13, 25, 26]. Our present study have illustrated that hsa_circ_0077837 elevation inhibited cell viability, migration, and invasion in NSCLC and enhanced apoptosis in vitro and inhibited tumorigenesis in vivo. Collectively, results demonstrated that hsa_circ_0077837 served to be anticancer gene in the progression of NSCLC.

Some circRNAs could interfere with the growth and development of tumor by being a sponge to miRNAs. Increasing studies also indicated that circRNA participated in the regulation of NSCLCs development by sponging miRNAs. For instance, circRNA_001010 can combine with miR-5112 to block its function to facilitate proliferation and metastasis in NSCLC [27]. Hsa_circRNA_103809 can combine with miR-337-3p as a sponge to release GOT1 in NSCLC cells. When hsa_circRNA_103809 was knocked down, we can see that this scenario can enhance the suppressive influence of cisplatin on cell proliferative ability and viability while induced cell apoptosis in NSCLC cells [28]. In the present study, we proved that hsa_circ_0077837 can serve as miR-1178-3p sponge, suggesting that miR-1178-3p might play important roles in NSCLC sponged by hsa_circ_0077837. Several studies have demonstrated that miR-1178-3p contributed to cancer progression. For instance, Wang et al. revealed that miR-1178-3p had positive action on nasopharyngeal carcinoma cell growth by targeting STK4 [29]. Bi et al. demonstrated that circ-ZKSCAN1 increased p21 protein expression by binding to miR-1178-3p, resulting in the suppression of bladder cancer [30]. Our previous study found that miR-1178-3p was higher in NSCLC in vitro and in vivo. Further analysis depicted that hsa_circ_0077837 effect on NSCLC cells was neutralized by miR-1178-3p. These results demonstrated that hsa_circ_0077837 functioned as a miR-1178-3p sponge, thus inhibiting NSCLC progression.

It has been accepted that miRNAs can release their effects by binding to 3’UTR of target miRNAs. Our study proved that APITD1 was one of the targets of miR-1178-3p. Figure 4: APITD1 was a downstream molecule of miR-1178-3p. (a) TargetScan predicted the potential binding site between miR-1178-3p and APITD1. (b) Dual-luciferase reporter assays detected the regulation of miR-1178-3p on APITD1, and the data were presented as mean±SEM, **P<0.01, miR-1178-3p mimics group vs. miR-1178-3p NC group. (c) miR-1178-3p expression was upregulated in 110 NSCLC tissues in comparison with 110 adjacent tissues, and U6 acted as a control, ***P<0.001, tumor group vs. adjacent group. (d) APITD1 level affected by miR-1178-3p was detected by western blot, and the data were presented as mean±SEM, ***P<0.001, miR-1178-3p mimics group vs. NC group; ###P<0.001, miR-1178-3p inhibitor group vs. NC group.
Figure 5: Continued.
Figure 5: Hsa_circ_0077837 inhibited NSCLC cell growth by modulating the miR-1178-3p/APITD1 pathway. (a–d) The viability, migration, invasion, and apoptosis of H1650 cells were detected via CCK-8, transwell, wound healing, and flow cytometry affected by miR-1178-3p or APITD1, respectively. *P < 0.05, **P < 0.01, ***P < 0.001, mimics group vs. NC group; *P < 0.05, **P < 0.01, ***P < 0.001, si-APITD1 group vs. NC group. (e–h) Rescue assays detected the rescue function of miR-1178-3p mimics or si-APITD1 to hsa_circ_0077837 elevation on viability, migratory, invasive, and apoptotic capabilities. **P < 0.01, ***P < 0.001, over-circ group vs. control group; *P < 0.05, ***P < 0.001, over-circ+mimics group vs. over-circ group; *P < 0.05, **P < 0.01, over-circ group+si-APITD1 group vs. over-circ group.

Figure 6: Continued.
Furthermore, APITD1 elevation could rescue miR-1178-3p mimics influence on cell growth. To sum up, our results demonstrated that hsa_circ_0077837 was a direct ceRNA that can sponge to miR-1178-3p in vitro and in vivo, thereby releasing the impact of APITD1 to inhibit the malignancy of NSCLC.

In summary, we clarified that hsa_circ_0077837 alleviated NSCLC progression via the hsa-miR-1178/EDNRA axis. These findings proposed a theoretical basis for the further targeted molecular therapy of NSCLC and have excellent reference value for guiding the individualized treatment of NSCLC.

Data Availability

The datasets during and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The authors thank the technical support from Zibo Central Hospital and Jiangsu University.

References

[1] B. C. Bade and C. S. Dela Cruz, “Lung cancer 2020,” *Clinics in Chest Medicine*, vol. 41, no. 1, pp. 1–24, 2020.
[2] J. Rodriguez-Canales, E. Parra-Cuentas, and E. Wistuba, “Diagnosis and molecular classification of lung cancer,” *Cancer Treatment and Research*, vol. 170, pp. 25–46, 2016.
[3] G. S. Jones and D. R. Baldwin, “Recent advances in the management of lung cancer,” *Clinical Medicine*, vol. 18, pp. s41–s46, 2018.
[4] R. Maconachie, T. Mercier, N. Navani, G. McVeigh, and C. Guideline, “Lung cancer: diagnosis and management: summary of updated NICE guidance,” *BMJ*, vol. 364, p. i1049, 2019.
[5] L. L. Chen and L. Yang, “Regulation of circRNA biogenesis,” *RNA Biology*, vol. 12, pp. 381–388, 2015.
[6] L. S. Kristensen, M. S. Andersen, L. V. W. Stagsted, K. K. Ebbesen, and T. B. Hansen, “The biogenesis, biology and characterization of circular RNAs,” *Nature Reviews Genetics*, vol. 20, pp. 675–691, 2019.
[7] T. Yu, Y. Wang, Y. Fan, N. Fang, and T. Wang, “CircRNAs in cancer metabolism: a review,” *Journal of Hematology & Oncology*, vol. 12, p. 90, 2019.
[8] H. D. Zhang, L. H. Jiang, D. W. Sun, J. C. Hou, and Z. L. Ji, “CircRNA: a novel type of biomarker for cancer,” *Breast Cancer*, vol. 25, pp. 1–7, 2018.
[9] C. Braicu, A. A. Zimta, A. Harangus, I. Iurca, and A. Irimie, “The function of non-coding RNAs in lung cancer tumorigenesis,” *Cancers*, vol. 11, 2019.
[10] C. Wang, S. Tan, J. Li, W. R. Liu, and Y. Peng, “CircRNAs in lung cancer - biogenesis, function and clinical implication,” *Cancer Letters*, vol. 492, pp. 106–115, 2020.
[11] L. Wang, X. Tang, Z. Zhou, S. Wang, and Z. Lei, “Circular RNA hsa_circ_0008305 (circPTK2) inhibits TGF-beta-induced epithelial-mesenchymal transition and metastasis by controlling TIF1gamma in non-small cell lung cancer,” *Molecular Cancer*, vol. 17, p. 140, 2018.
[12] Y. Zhao, R. Zheng, J. Chen, and D. Ning, “CircRNA CDR1as/miR-641/HOXA9 pathway regulated stemness contributes to cisplatin resistance in non-small cell lung cancer (NSCLC),” *Cancer Cell International*, vol. 20, p. 289, 2020.
[13] D. Hang, J. Zhou, N. Qin, W. Zhou, and H. Ma, “A novel plasma circular RNA circFARSA is a potential biomarker for non-small cell lung cancer,” *Cancer Med*, vol. 7, pp. 2783–2791, 2018.
[14] J. T. Yao, S. H. Zhao, Q. P. Liu, M. Q. Lv, and D. X. Zhou, “Over-expression of CircRNA_100876 in non-small cell lung cancer and its prognostic value,” *Pathology, Research & Practice*, vol. 213, pp. 453–456, 2017.
[15] C. Wang, S. Tan, W. R. Liu, Q. Lei, and W. Qiao, “RNA-Seq profiling of circular RNA in human lung adenocarcinoma and squamous cell carcinoma,” *Molecular Cancer*, vol. 18, p. 134, 2019.
[16] A. M. Romaszko and A. Doboszynska, “Multiple primary lung cancer: a literature review,” *Advances in Clinical and Experimental Medicine*, vol. 27, pp. 725–730, 2018.

![Figure 6: Hsa_circ_0077837 overexpression inhibited tumor growth in vivo. (a) Relative hsa_circ_0077837 level was detected by qRT-PCR, and GAPDH act as a control. (b) The tumor volume and weight were lower in over-hsa_circ_0077837 group while higher in si-hsa_circ_0077837 group. (c) Ki-67 immunohistochemistry detected proliferation in over-hsa_circ_0077837 or si-hsa_circ_0077837 group. (d) qRT-PCR analysis detected miR-1178-3p expression in the over-hsa_circ_0077837 or si-hsa_circ_0077837 group. (e) APITD1 expression was detected by western blot. (f) TUNEL staining of the tumors. The data were presented as mean ± SEM. **P < 0.01, ***P < 0.001, over-hsa_circ_0077837 group vs. control group. # # # P < 0.01, ### P < 0.001, si-hsa_circ_0077837 group vs. control group.](image-url)
[17] M. Evans, "Lung cancer: needs assessment, treatment and therapies," *British Journal of Nursing*, vol. 22, no. S18, pp. S20–S12, 2013.

[18] J. Salzman, "Circular RNA expression: its potential regulation and function," *Trends in Genetics*, vol. 32, pp. 309–316, 2016.

[19] K. Y. Hsiao, H. S. Sun, and S. J. Tsai, "Circular RNA: new member of noncoding RNA with novel functions," *Proceedings of The Society for Experimental Biology and Medicine*, vol. 242, pp. 1136–1141, 2017.

[20] Z. Z. Liang, C. Guo, M. M. Zou, P. Meng, and T. T. Zhang, "circRNA-miRNA-mRNA regulatory network in human lung cancer: an update," *Cancer Cell International*, vol. 20, p. 173, 2020.

[21] C. Nicot, "RNA-Seq reveal the circular RNAs landscape of lung cancer," *Molecular Cancer*, vol. 18, p. 183, 2019.

[22] C. Zhang, L. Ma, Y. Niu, Z. Wang, and X. Xu, "Circular RNA in lung cancer research: biogenesis, functions, and roles," *International Journal of Biological Sciences*, vol. 16, pp. 803–814, 2020.

[23] N. Zhang, A. Nan, L. Chen, X. Li, and Y. Jia, "Circular RNA circSATB2 promotes progression of non-small cell lung cancer cells," *Molecular Cancer*, vol. 19, p. 101, 2020.

[24] Z. F. Zhou, Z. Wei, J. C. Yao, S. Y. Liu, and F. Wang, "CircRNA_102179 promotes the proliferation, migration and invasion in non-small cell lung cancer cells by regulating miR-330-5p/HMGB3 axis," *Pathology, Research & Practice*, vol. 216, p. 153144, 2020.

[25] L. Li, M. Du, C. Wang, and P. He, "Reduced expression of circRNA novel_circ_0005280 and its clinical value in the diagnosis of non-small cell lung cancer," *Journal of Thoracic Disease*, vol. 12, pp. 7281–7289, 2020.

[26] L. Zong, Q. Sun, H. Zhang, Z. Chen, and Y. Deng, "Increased expression of circRNA_102231 in lung cancer and its clinical significance," *Biomedicine & Pharmacotherapy*, vol. 102, pp. 639–644, 2018.

[27] Q. Wang and P. M. Kang, "CircRNA_001010 adsorbs miR-5112 in a sponge form to promote proliferation and metastasis of non-small cell lung cancer (NSCLC)," *European Review for Medical and Pharmacological Sciences*, vol. 24, pp. 4271–4280, 2020.

[28] X. Zhu, J. Han, H. Lan, Q. Lin, and Y. Wang, "A novel circular RNA hsa_circRNA_103809/miR-377-3p/GOT1 pathway regulates cisplatin-resistance in non-small cell lung cancer (NSCLC)," *BMC Cancer*, vol. 20, p. 1190, 2020.

[29] L. Q. Wang, A. C. Deng, L. Zhao, Q. Li, and M. Wang, "MiR-1178-3p promotes the proliferation, migration and invasion of nasopharyngeal carcinoma Sune-1 cells by targeting STK4," *Journal of Biological Regulators & Homeostatic Agents*, vol. 33, pp. 321–330, 2019.

[30] J. Bi, H. Liu, W. Dong, W. Xie, and Q. He, "Circular RNA circ-ZKSCAN1 inhibits bladder cancer progression through miR-1178-3p/p21 axis and acts as a prognostic factor of recurrence," *Molecular Cancer*, vol. 18, p. 133, 2019.

[31] C. Krona, K. Ejeskar, H. Caren, F. Abel, and R. M. Sjoberg, "A novel 1p36.2 located gene, APITD1, with tumour-suppressive properties and a putative p53-binding domain, shows low expression in neuroblastoma tumours," *British Journal of Cancer*, vol. 91, pp. 1119–1130, 2004.